HCPCS code J9303 – Panitumumab (Vectibix) injection, per 10 mg

Key takeaways

HCPCS code J9303 covers panitumumab (Vectibix) and is billed per 10 mg, so a 480 mg dose is reported as 48 units.

Vectibix is FDA-approved for RAS wild-type metastatic colorectal cancer and, with sotorasib, for previously treated KRAS G12C-mutated disease.

Dosing is 6 mg/kg every 14 days, so the unit count changes with each patient’s weight.

Vectibix ships in 100 mg and 400 mg single-dose vials, so Medicare claims carry JW for discarded drug or JZ when none is discarded.

In Pabau’s practice software, the infusion note, vial details and claim lines sit in one patient record, so units are never rebuilt by hand.

HCPCS Code J9303: Definition and official descriptor

HCPCS Code J9303 is the CMS Level II code for “injection, panitumumab, 10 mg.”

It sits in the J9000–J9999 chemotherapy drug range of the J-series, within the wider set of HCPCS Level II codes. The code identifies Vectibix, the panitumumab product made by Amgen. CMS made J9303 effective on January 1, 2008, replacing temporary code C9235.

One unit of J9303 equals 10 mg of panitumumab. Panitumumab is a human IgG2 monoclonal antibody that blocks the epidermal growth factor receptor (EGFR). It is given by intravenous infusion.

FDA-approved indications and ICD-10 diagnosis codes

Vectibix is FDA-approved for two metastatic colorectal cancer (mCRC) settings, per its current prescribing information. Each one depends on a biomarker result from an FDA-approved test.

• RAS wild-type mCRC: First-line with FOLFOX, or as monotherapy after progression on fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy.
• KRAS G12C-mutated mCRC: In combination with sotorasib (Lumakras), after prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.
• Not indicated: Other RAS-mutant mCRC, or mCRC where the RAS status is unknown.

Wild-type means no mutation in exons 2, 3 or 4 of either KRAS or NRAS. The sotorasib combination needs a confirmed KRAS G12C mutation instead. Keep the report that applies in the chart before the first dose.

Traditional Medicare can also cover an off-label anticancer use when a recognized compendium, such as NCCN, supports it. That rule sits in the Medicare Benefit Policy Manual, Chapter 15, section 50.4.5. Commercial plans set their own drug policies, so check the plan first.

How to calculate J9303 units

Divide the milligrams administered by 10 to get J9303 units. Vectibix is dosed at 6 mg/kg every 14 days, so the unit count follows each patient’s weight.

Unit and waste calculation example

An 80 kg patient receives 480 mg, which is 48 units. Drawing that dose takes one 400 mg vial and one 100 mg vial, so 20 mg is left over. That 20 mg goes on a second line as 2 units with modifier JW.

The vial mix decides the waste as much as the dose does. Ask the pharmacy to record which vials it opened, so the JW line matches the drug purchased.

JW and JZ modifiers for Vectibix

Both Vectibix vials are single-dose, and the label says to discard any unused portion. Since July 1, 2023, Medicare Part B has required modifier JW on discarded drug and JZ when none is discarded.

Report the administered units on one line and the discarded units on a second line with JW. Record the discarded amount in the patient’s chart. Medicaid and commercial plans set their own wastage rules, so confirm them before billing a JW line.

Codes to bill alongside J9303

Vectibix is given by intravenous infusion, so the J9303 line is billed with an administration code. Monoclonal antibodies such as panitumumab use the chemotherapy administration codes.

Doses up to 1,000 mg run over 60 minutes, so most visits bill 96413 alone. The label allows 30 to 60 minutes for later infusions once the first is tolerated. Doses above 1,000 mg run over 90 minutes, which still does not reach the 96415 threshold.

Physician offices bill on the 837P or CMS-1500 with place of service 11. Hospital outpatient departments bill on the institutional claim, usually under revenue code 0636.

Codes commonly confused with HCPCS Code J9303

Mix-ups usually come from drugs in the same class, drugs used in the same colorectal regimens, or an outdated code list.

Two errors cost the most time. Billing J9999 when J9303 exists invites a denial and a slow appeal. A J2513 line for Vectibix bills a deleted fluid code, so the claim denies outright.

Medicare coverage and reimbursement for J9303

Medicare Part B covers J9303 under buy-and-bill. The practice buys Vectibix, administers it and bills Medicare for the drug and the infusion.

Medicare pays separately payable Part B drugs at average sales price (ASP) plus 6%, in physician offices and hospital outpatient departments alike. Sequestration then trims 2% from the Medicare payment.

CMS updates ASP payment limits every quarter. Offices take the rate from the CMS ASP pricing files, and hospitals from OPPS Addendum B. Check the current quarter before quoting expected payment.

Prior authorization requirements

Traditional Medicare does not require prior authorization for J9303. Medicare Advantage plans, Medicaid plans and most commercial payers often do, so check each plan before the first cycle.

• Typical PA documentation: The pathology report, the RAS or KRAS G12C result, the oncologist’s treatment plan and any prior lines of therapy.
• Decision timeframes: Medicare Advantage plans must answer expedited requests within 72 hours. Since January 2026, standard requests get an answer within 7 calendar days.
• Local coverage: Check your Medicare Administrative Contractor’s site for any local coverage article on panitumumab before the first claim.

Tracking authorization status next to the claim queue stops a J9303 claim from going out before approval lands. A claim sent without approval is among the costliest denials for this drug.

National Drug Code (NDC) reporting requirements

Medicaid programs require the NDC on physician-administered drug claims so states can collect manufacturer rebates. Many commercial payers ask for it as well, and a missing NDC can deny the line.

Vectibix NDCs

The label also lists package codes ending in -21 for each vial. Bill the NDC printed on the carton you used.

How to format the NDC on the claim

• Report the 11-digit NDC in 5-4-2 format, with no hyphens or spaces, on both 837P and CMS-1500 claims.
• On the 837P, use qualifier N4 in Loop 2410. On the CMS-1500, enter N4 and the NDC in the shaded area of box 24A.
• Report the NDC quantity with its own unit of measure, such as ML. It is separate from the HCPCS units, which count 10 mg steps.
• A full 400 mg vial holds 20 mL of solution, but it equals 40 units of J9303.

A frequent slip is copying the NDC from the last claim after the vial mix changed. Pull it from the dispensing record for that infusion date.

Common claim denial reasons for J9303 and how to avoid them

J9303 denials follow a predictable pattern. The table maps each one to its fix, and the wider denial management in healthcare process applies to drug claims too.

Documentation requirements to support J9303 claims

Sound medical billing compliance for panitumumab starts with the right documents in the chart before the claim goes out. A missing document found in a post-payment audit costs more to fix than one caught beforehand. Clean claim submission habits cut both first-pass denials and audit exposure.

• Pathology report: Colorectal adenocarcinoma with the site documented (colon, rectosigmoid junction or rectum).
• Biomarker report: KRAS and NRAS wild-type status across exons 2, 3 and 4, dated before the first dose. The sotorasib combination needs a KRAS G12C result instead.
• Treatment plan: The indication, any prior therapy and the 6 mg/kg dose with the weight it was based on.
• Infusion record: Date, start and stop times, drug, lot number, milligrams given and the administering clinician.
• Waste record: The vials opened and the milligrams discarded, matching the JW line.
• Purchase records: The invoice or dispensing record that supports the NDC reported.
• Advance Beneficiary Notice (ABN): Signed before the infusion when Medicare is expected to deny the dose as not reasonable and necessary.

Practices moving infusion records off paper should map these fields between the infusion system and billing. Our guide to medical billing workflows covers how a charge moves from the chart to the claim.

How Pabau keeps J9303 claims in step from infusion to payment

Vectibix claims tend to break at the hand-off. The weight is in the visit note, the vial NDC on the carton and the waste in a nurse’s log. A biller then rebuilds the claim from all three.

Pabau holds the treatment note, dose and stock records in one patient record. Its claims management software builds the claim from that record, so the logged milligrams and waste carry through to the claim lines.

Scheduling covers the 14-day cycle. Booking each infusion two weeks out, with an automated reminder, keeps the regimen inside the dates the authorization covers.

Track Vectibix billing from dose to claim

Pabau records the dose, vial NDC and discarded milligrams at the infusion. J9303 claims go out with the right units and modifiers, and the audit trail is already in place.

Book a demo

Conclusion

J9303 unit math is simple, with one unit for every 10 mg. Claims fail when the vial mix, the waste line or the biomarker report gets pieced together after the infusion.

Set the vial logic and the JW or JZ rule once in your charge capture. Tie each claim to a labeled indication, and every 14-day cycle bills the same way.

To see how Pabau keeps Vectibix doses, vial records and claim lines together, book a demo.

Continue your research

Need a framework for reducing oncology billing denials? Denial management in healthcare covers the end-to-end process for tracking, appealing, and preventing claim rejections across drug and procedure codes.

Want to understand how drug claims move through payers? What is revenue cycle management explains the full billing lifecycle from verification through payment posting, with a focus on reducing leakage.

Looking for guidance on superbill and claim export formats? Superbill billing guide covers how to structure drug and procedure line items for clean claim submission.

Frequently asked questions